ERG and FLI1 Binding Sites Demarcate Targets for Aberrant Epigenetic Regulation by AML1-ETO in Acute Myeloid Leukemia
Overview
Authors
Affiliations
ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA-mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins, such as AML1-ETO and PML-RAR-α, involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together, these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.
Heuts B, Martens J Front Mol Biosci. 2023; 10:1266697.
PMID: 37886034 PMC: 10598665. DOI: 10.3389/fmolb.2023.1266697.
SCN4B inhibits the progression of lung adenocarcinoma and is associated with better prognosis.
Ma M, Guo B, Lu H, Hong L Clin Respir J. 2023; 17(12):1233-1245.
PMID: 37826914 PMC: 10730470. DOI: 10.1111/crj.13709.
Azlan A, Khor K, Rajasegaran Y, Rosli A, Said M, Mohd Yusoff N Med Oncol. 2023; 40(7):208.
PMID: 37341821 DOI: 10.1007/s12032-023-02075-w.
A RUNX1/ETO-SKP2-CDKN1B axis regulates expression of telomerase in t (8;21) acute myeloid leukemia.
Moses E, Azlan A, Khor K, Mot Y, Mohamed S, Seeni A Cell Mol Life Sci. 2023; 80(3):70.
PMID: 36820913 PMC: 11071865. DOI: 10.1007/s00018-023-04713-y.
Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T Blood Adv. 2022; 7(8):1577-1593.
PMID: 36269819 PMC: 10139867. DOI: 10.1182/bloodadvances.2022008018.